tbuckley/cabot-search huggingface dataset:
Did the 2004 World Health Organization (WHO) histologic classification result in better prognostic categories for resected thymomas as compared to 1999 WHO classification scheme?
Authors: Yousif Yonan, Dani Zander, John M. Varlotto, Jennifer Toth, Michael Reed, Christopher Gilbert, John Charles Flickinger, Abram Recht, Chandra Prakash Belani, Malcolm M. DeCamp
Journal: Journal of Clinical Oncology (2013)

e18552 Background: The classification of thymic epithelial neoplasms is subject of controversy. The purpose of our investigation is to see whether the 2004 histologic classification results in better prognostic categories than that of the 1999 classification. Methods: The SEER 18 database was used to investigate incidence and overall survival/cause-specific survival (OS/CSS) of resected thymomas during 2000-2009. Incidence was examined by frequency and trend analyses. Patients diagnosed with first primary localized thymoma/thymic carcinoma were selected in two time periods (2000-2003: N=201; 2005-2009: N = 497). The median follow up is 79 months and 27 months respectively. OS/CSS in two patients group were analyzed by Kaplan-Meier estimation, log-rank tests, and multivariate proportional hazards modeling. Results: The proportion of six histology categories (A, AB, B1-B3,C) did not change significantly during the two time periods. Compared to patients diagnosed in 2000-2003, OS was not significantly different in patients diagnosed in 2005-2009 in the log rank tests or multivariate analysis after accounting for treatment, tumor factors, and patient characteristics (OS, HR=0.737, p=0.1580; CSS, HR=0.731, p=0.3711). Histology as 6 categories is a significant predictor for OS in the multivariate analysis in 2005-2009, but not in 2000-2003. However, the predictive role of histology is similar in both time periods in the multivariate analysis of CSS. Complete resection, classification C, and tumor stage are significantly linked to OS and CSS. Conclusions: Patients diagnosed after 2004 did not have better survival outcomes than earlier patients. The WHO classification of 2004 may be a better predictor of OS than that of 1999 as shown by the wide-spectrum of pathologists reporting to SEER.
Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States
Authors: Paul J. Joudrey, E. Jennifer Edelman, Emily A. Wang
Journal: JAMA (2019)

This study characterizes driving distances to opioid treatment programs in urban vs rural counties in states with the highest rates of opioid mortality and compares them with distances to methadone-prescribing federally qualified health centers and dialysis centers.
Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Authors: L. Mendonça, A. Trindade, C. Carvalho, J. Correia, M. Badenes, J. Gigante, A. Duarte
Journal: Annals of Oncology (2019)
The analysis of current treatment outcomes in melanoma patients with brain metastases
Authors: J. Placzke, P. Teterycz, I. Lugowska, T. Morysinski, A. Borkowska, T. Switaj, A. Klimczak, K. Kozak, P. Rogala, H. Kosela-Paterczyk, M.E. Dudzisz-Sledz, M. Spalek, A.M. Czarnecka, P. Rutkowski
Journal: Annals of Oncology (2019)
Downregulation of Mir-146a-5p, Mir-99b-5p, Mir-143-3p, Mir-10a-5p and Mir-151a-3p Associated with PI3K/AKT, p53, NF-Kb, and Fanconi Anemia/BRCA Signaling Pathways Are Observed in Imatinib-Resistant Chronic Myeloid Leukemia Patients without Detectable BCR-ABL kinase Domain Mutations
Authors: Ernie Yap, Zainul Abidin Norziha, Alfred Simbun, Nor Rafeah Tumian, Soon Keng Cheong, Chooi Fun Leong, Chieh Lee Wong
Journal: Blood (2016)
A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy
Authors: P. Dirix, M. Strijbos, K. Fransis, N. Liefhooghe, S. Van Bruwaene, P. Uvin, C. Ghysel, D. Ost, B. Engels, R. Van den Begin, F.-X. Otte, T. Roumeguere, S. Palumbo, Y. Neybuch, V. Fonteyne, L. Renard, W. Everaerts, B. Tombal, P. Ost, L.Y. Dirix
Journal: Annals of Oncology (2019)
A p53-MDM2 Interaction Inhibitor, DS-5272, Inhibits the Development of MLL-Fusion Leukemia with the Assistance of Tumor Immunity
Authors: Susumu Goyama, Yasutaka Hayashi, XiaoXiao Liu, Shiori Shikata, Yosuke Tanaka, Tomofusa Fukuyama, Akiko Matsumoto, Satoshi Yamasaki, Tatsuhiro Shibata, Toshio Kitamura
Journal: Blood (2017)
A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC)
Authors: R. Itotani, S. Matsumoto, H. Udagawa, K. Nishino, I. Nakachi, S. Miyamoto, S. Hara, S. Kuyama, N. Ebi, Y. Tsubata, M. Shingyoji, T. Kato, Y. Ohe, K. Nishi, S. Hashimoto, K. Goto
Journal: Annals of Oncology (2019)
Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients
Authors: T. Sugano, M. Seike, Y. Saito, N. Takano, K. Hisakane, S. Takahashi, T. Tanaka, T. Kashiwada, S. Nakamichi, S. Takeuchi, A. Miyanaga, Y. Minegishi, R. Noro, K. Kubota, A. Gemma
Journal: Annals of Oncology (2019)
G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial
Authors: Anna B Halpern, Emily M Huebner, Megan Othus, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, Kelda M Gardner, Sarah A Buckley, Elihu H. Estey, Roland B. Walter
Journal: Blood (2017)
Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,
Authors: Philipp D. le Coutre, Francis J. Giles, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, Dong-Wook Kim, Susan Branford, Martin C. Müller, Yaping Shou, Steven Novick, Xiaolin Fan, Jorge E. Cortes, Michele Baccarani, Hagop M. Kantarjian
Journal: Blood (2011)
Multigene panel testing results for hereditary breast cancer in 1325 individuals: Implications for gene selection and considerations for guidelines
Authors: G.N. Tsaousis, N. Tsoulos, E. Papadopoulou, K. Agiannitopoulos, G. Pepe, N. Diamantopoulos, T.I. Floros, R. Iosifidou, C. Markopoulos, K. Papazisis, V. Venizelos, G. Xepapadakis, E. Banu, D.T. Eniu, D.L. Stanculeanu, A. Ungureanu, S. Tansan, M. Tekinel, S. Yalcin, G. Nasioulas
Journal: Annals of Oncology (2019)
Government imposes new restrictions on HRT exports to tackle shortages
Authors: Jacqui Wise
Journal: BMJ (2019)

The UK government has announced new measures to tackle the current shortages of hormone replacement therapy (HRT) which are affecting thousands of patients in the UK, with problems expected to continue well into next year.

There will be new restrictions to stop parallel exporting of HRT products while the current manufacturing problems are resolved. This will stop drug wholesalers from buying medicines meant for UK patients then selling them on for a higher price in another country.

The Department of Health and Social Care said a total of 19 HRT products will be subject to parallel export restrictions as well as a further five drugs, including all adrenaline auto-injectors and hepatitis B …
Eltrombopag for Prolonged Post-Transplant Hyporigenerative Cytopenias
Authors: Luana Marano, Serena Marotta, Fabiana Cacace, Camilla Frieri, Luigia Simeone, Fabio Trastulli, Selenia Vitiello, Flora Cardano, Fabrizio Pane, Antonio M. Risitano
Journal: Blood (2018)
Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: A retrospective study of potential prognostic and predictive biomarkers
Authors: E.M. Al-ezzi, Z.W. Veitch, S. Salah, T. Van der Kwast, T. Stockley, E. Malone, S. Sridhar, A.G. Sacher, N. Fallah-rad, G. Kulkarni, A. Zlotta, A. Finelli, A.R. Hansen
Journal: Annals of Oncology (2019)
Doctor who practised “functional medicine” is suspended for nine months
Authors: Clare Dyer
Journal: BMJ (2019)

A specialist in alternative “functional medicine” has been suspended from the UK medical register for nine months after a tribunal found that he “persistently overdiagnosed thyroid problems” and treated patients with drugs that were not clinically indicated.

Georges Mouton, 62, practises privately from a clinic in London’s West End. Functional medicine, said to be a holistic approach that focuses on the root causes of disease, is not recognised in the UK.

The General Medical Council’s allegations against Mouton accused him of ordering unnecessary or unproved tests, sometimes without obtaining proper consent, on eight patients treated between 2013 and 2016.

Wrongly interpreting the test results as evidence of thyroid problems, sometimes without considering obvious …
ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma
Authors: B.A. Van Tine, M.O. Butler, D. Araujo, M.L. Johnson, J. Clarke, D. Liebner, K. Odunsi, A.J. Olszanski, S. Basu, F. Brophy, T. Holdich, T. Trivedi, R.G. Amado, D.S. Hong
Journal: Annals of Oncology (2019)
Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour
Authors: B. Hrinczenko, D. Spigel, N. Iannotti, H.P. Safran, M.H. Taylor, J. Bennouna, S. Goel, J. Leach, D.J. Wong, K. Kelly, C. Verschraegen, M. Bajars, J. Manitz, M. Ruisi, J.L. Gulley
Journal: Annals of Oncology (2019)
Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study
Authors: J Vidal Barrull, D. Casadevall, M.C. Fernandez, M. Castro-Henriques, P. García-Alfonso, B. Martin-Cullell, V. Alonso-Orduna, R M Rodríguez Alonso, M. Benavides, C Santos Vivas, E Elez Fernández, R. Garcia-Carbonero, R. Ferreiro, J.L. Manzano, F. Losa, R. Salazar, J. Tabernero, E Aranda Aguilar, B. Bellosillo, C Montagut Viladot
Journal: Annals of Oncology (2019)
Molecular modeling of high-affinity interactions between phosphopeptides and the SH2 domain of Stat3
Authors: John McMurray, Zhiyong Ren, Pijus Mandal, Xiaomin Chen
Journal: Cancer Research (2007)

3180  Stat3 (signal transducer and activator of transcription) is constitutively active in several cancer types and is a target for anti-cancer drug design. Compounds targeted to the SH2 domain would uncouple this protein from its roles in the aberrant survival and cell cycling pathways that characterize cancer cells. The design of peptidominetics targeted to Stat3 would be greatly aided by a model of phosphopeptides bound to the SH2 domain. The SH2 domains of four STAT proteins crystallized to date show remarkably high tertiary structure overlap. In comparison to the SH2 domains of non-STAT proteins such as Grb-family adapters, p85PI3K, Src-family kinases, etc, the STATs have sequence deletions in the EF loop region. Instead, they have a pocket that resides between beta strand D and a unique helix. We used the X-ray structure of the complex of Stat1 and Ac-pTyr-Asp-Lys-Pro-His [1] as a template to propose a model of interactions between pTyr-Xxx-Xxx-Gln peptides and Stat3. Ac-pTyr-Leu-Pro-Gln-NHBn [2] was docked into the SH2 domain of Stat3 using InsightII and the assembly was subjected to energy minimization. In addition to the “standard” phosphotyrosine interactions, the complex reveals peptide backbone-protein hydrogen bonds between Leu NH and C=O, Pro C=O and the NH of the benzyl amide that are in keeping with results of structure-activity studies published previously [2]. These interactions are unique to STAT-peptide interactions. The CONH2 of Gln resides in a pocket between beta strand D and the unique helix and can form hydrogen bonds with the main chain carbonyl groups of Pro639 and Tyr640. Beta-substituted Gln analogues bind poorly supporting a tight interaction in the proposed pocket. The model proposed in this study has potential use in the design of peptidomimetic inhibitors of Stat3.  1. Mao et al Mol. Cell 17:761-71, 2005  2. Coleman et al. J.Med. Chem. 48:6661, 2005
SAT0457 PATTERNS AND CONSEQUENCES OF POST-CHIKUNGUNYA ARTHRITIS – A LONGITUDINAL STUDY IN A TERTIARY CARE HOSPITAL IN BANGLADESH
Authors: Sigma Hossain, Minhaj Choudhury, Surayea Yeasmin, MD. Masudul Hassan, MD. Ariful Islam
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Chikungunya fever (CF), is a viral illness, characterized by 3–7 days of high fever, headache, rash, myalgia, and severe arthralgias/arthritis, the hallmark of the disease.<sup>1</sup> There is evidence that links Chikungunya infection (CHIKV) with development of unspecific Post-Viral Arthritis, Rheumatoid Arthritis, Seronegative Spondylitis and other non-inflammatory musculoskeletal complaints like persistent arthralgia.<sup>2</sup> <h3>Objectives:</h3> To identify the clinical patterns and consequences of Post-Chikungunya arthritis. <h3>Methods:</h3> This longitudinal study was carried out during a major out-break of CHIKV infection in Dhaka, Bangladesh, among 142 patients (CHIKV IgM and/or IgG positive) who were followed-up for the next one year. Their clinical, laboratory, radiographic and ultrasonographic features were evaluated. Functional status was assessed by validated Bengali version of Health Assessment Questionnaire (HAQ). <h3>Results:</h3> The mean age of the patient's was 43.12 ±10.94 where 50.7% were male and 81.7% were urban resident. At presentation (D1),95.1% patients were Chikungunya IgM positive where as 20.4% were IgG positive. Polyarthritis was noted among 69.7% patients. Symmetrical joint involvement and joint swelling were present in 84.5% in 47.2% patients respectively. The mean HAQ score was 1.34±0.72. After 3 months (D90) follow up, 40.8% patients reported Chronic Chikungunya arthritis where 6.9% had Rheumatoid Arthritis, 3.4% had Spondyloarthropathy and 89.6% were Undifferentiated arthritis. Among the Chronic Chikungunya arthritis patients, 5.2% were Anti-CCP positive, 1.7% were Rheumatoid factor positive, 3.4% were HLA-B27 positive and 3.4% had X-Ray findings of bilateral Sacroiliitis. Patients were treated with NSAID (100.0%) and steroid (10.0%) initially. Chronic arthritis was treated with Sulfasalazine (12.0%), Methotrexate (7.0%) and <i>Tofacitinib</i> (3.4%). <h3>Conclusion:</h3> This study demonstrated that chronic arthritis was a frequent complication of acute Chikungunya infection where majority had undifferentiated arthritis. <h3>References</h3> [1] Brighton SW, Prozesky OW, de la Harpe AL (1983) Chikungunya virus infection — a retrospective study of 107 cases. S Afr Med J63,313-5. [2] Yaseen HM, Simon F, Deparis X, Marimoutou C (2014) Identification of initial severity determinants to predict arthritis after chikungunya infection in a cohort of French gendarmes. BMC musculoskeletal disorders15,249. <h3>Disclosure of Interests:</h3> None declared
Outcomes of patients with melanoma brain metastases (MBM) treated with standard of care therapy after being excluded from MBM-specific clinical trials
Authors: K. Holbrook, M.P. Shephard, L. Haydu, I Glitza Oliva, R.N. Amaria, S. Patel, A. Diab, P. Hwu, C. Brown, I Boesch Arnold, E. Burton, M.A. Davies, H.A. Tawbi
Journal: Annals of Oncology (2019)
A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Authors: K.N. Chi, D. Rathkopf, G. Attard, M.R. Smith, E. Efstathiou, D. Olmos, E.J. Small, J.Y. Lee, P. Sieber, C. Dunshee, D. Ricci, J.S. Simon, X. Zhao, N. Kothari, S. Cheng, S.K. Sandhu
Journal: Annals of Oncology (2019)
Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields
Authors: Jason Gorman, Rosemarie D. Mason, Leonard Nettey, Nicole Cavett, Gwo-Yu Chuang, Dongjun Peng, Yaroslav Tsybovsky, Raffaello Verardi, Richard Nguyen, David Ambrozak, Kristin Biris, Celia C. LaBranche, Akshaya Ramesh, Chaim A. Schramm, Jing Zhou, Robert T. Bailer, Thomas B. Kepler, David C. Montefiori, Lawrence Shapiro, Daniel C. Douek, John R. Mascola, Mario Roederer, Peter D. Kwong
Journal: Immunity (2019)
Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients
Authors: M. Nieva, C. Fabregat, S. Tous, M. Mena, A. Teulé, A. Lozano, X. León, M. Guix, T. Bonfill, R. Mesía, L. Alemany, M. Taberna
Journal: Annals of Oncology (2019)
Immune microenvironment modulation by p14/ARF in malignant pleural mesothelioma
Authors: G. Pasello, L. Urso, A. Boscolo, F. Pezzuto, M. Silic-Benussi, S. Vuljian, S. Frega, L. Bonanno, M. Schiavon, F. Rea, V. Ciminale, P.F. Conte, F. Calabrese
Journal: Annals of Oncology (2019)
Abstract 19099: The Pro-Hypertrophic High Molecular Weight Fgf2 Activates Ampk or Erk by Engaging, Respectively, Fgfr1-Independent or Fgfr1-Dependent Pathways
Authors: Navid Koleini, Barbara E Nickel, Robert R Fandrich, Peter A Cattini, Elissavet Kardami
Journal: Circulation (2016)

Fibroblast growth factor 2 (Fgf2) is a multifunctional protein produced as >20 kDa high (Hi-) or 18 kDa low (Lo-) molecular weight isoforms in the heart. Both types of isoforms are secreted and exert similar (acute cardioprotection) and isoform-selective effects; the latter include stimulation of cardiomyocyte hypertrophy by Hi- but not Lo-Fgf2. It is not known if Fgf2 isoforms can activate the same receptors in cardiomyocytes. Since FGFR1 is a major cardiomyocyte receptor we used FGFR1 inhibitors to test the hypothesis that Fgf2 may activate Erk (a central signal in multiple pathways) or AMP-activated kinase (Ampk), a kinase regulating cardiac metabolism, regardless of FGFR1 activation, in an isoform-selective manner. Methods/Results: Primary cultures of neonatal rat cardiomyocytes were stimulated with Hi- or Lo-Fgf2, in the absence or presence of pharmacological FGFR1 inhibitors including SU5402 and PD173074. Activation of FGFR1, AMPK, ERK, and p38 were assessed by western blotting with corresponding ph...
Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations
Authors: Sarkawt Hamad, Daniel Derichsweiler, Symeon Papadopoulos, Filomain Nguemo, Tomo Šarić, Agapios Sachinidis, Konrad Brockmeier, Jürgen Hescheler, Bastiaan J Boukens, Kurt Pfannkuche
Journal: Theranostics (2019)

Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) are promising candidates to treat myocardial infarction and other cardiac diseases. Such treatments require pure cardiomyocytes (CMs) in large quantities. Methods: In the present study we describe an improved protocol for production of hiPSC-CMs in which hiPSCs are first converted into mesodermal cells by stimulation of wingless (Wnt) signaling using CHIR99021, which are then further differentiated into CM progenitors by simultaneous inhibition of porcupine and tankyrase pathways using IWP2 and XAV939 under continuous supplementation of ascorbate during the entire differentiation procedure. Results: The protocol resulted in reproducible generation of >90% cardiac troponin T (TNNT2)-positive cells containing highly organized sarcomeres. In 2D monolayer cultures CM yields amounted to 0.5 million cells per cm2 growth area, and on average 72 million cells per 100 mL bioreactor suspension culture without continuous perfusion. The differentiation efficiency was hardly affected by the initial seeding density of undifferentiated hiPSCs. Furthermore, batch-to-batch variations were reduced by combinatorial use of ascorbate, IWP2, and XAV939. Conclusion: Combined inhibition of porcupine and tankyrase sub-pathways of Wnt signaling and continuous ascorbate supplementation, enable robust and efficient production of hiPSC-CMs.
Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Authors: P. Heudel, D. Hooijenga, R. Phan, V. Augusto, X. Xie, C. Terret, C. Faure, S. Racadot, O. Tredan, T. Bachelot
Journal: Annals of Oncology (2019)
Safety of Lumbar Puncture (LP) and Instillation of Intrathecal (IT) Chemotherapy during Thrombocytopenia in Adults with Acute Lymphocytic Leukemia (ALL).
Authors: Ehab Atallah, Susan O’Brien, Susan Kaled, Alice Lynn, Jorge Cortes, Hagop Kantarjian, Deborah A. Thomas
Journal: Blood (2007)
Catalytic inactivation of influenza virus by iron oxide nanozyme
Authors: Tao Qin, Ruonan Ma, Yinyan Yin, Xinyu Miao, Sujuan Chen, Kelong Fan, Juqun Xi, Qi Liu, Yunhao Gu, Yuncong Yin, Jiao Hu, Xiufan Liu, Daxin Peng, Lizeng Gao
Journal: Theranostics (2019)

Influenza poses a severe threat to human health in the world. However, developing a universal anti-viral strategy has remained challenging due to the presence of diverse subtypes as well as its high mutation rate, resulting in antigenic shift and drift. Here we developed an antiviral strategy using iron oxide nanozymes (IONzymes) to target the lipid envelope of the influenza virus. Methods: We evaluated the antiviral activities of our IONzymes using a hemagglutination assay, together with a 50% tissue culture infectious doses (TCID50) method. Lipid peroxidation of the viral envelope was analyzed using a maleic dialdehyde (MDA) assay and transmission electron microscopy (TEM). The neighboring viral proteins were detected by western blotting. Results: We show that IONzymes induce envelope lipid peroxidation and destroy the integrity of neighboring proteins, including hemagglutinin, neuraminidase, and matrix protein 1, causing the inactivation of influenza A viruses (IAVs). Furthermore, we show that our IONzymes possess a broad-spectrum antiviral activity on 12 subtypes of IAVs (H1~H12). Lastly, we demonstrate that applying IONzymes to a facemask improves the ability of virus protection against 3 important subtypes that pose a threat to human, including H1N1, H5N1, and H7N9 subtype. Conclusion: Together, our results clearly demonstrate that IONzymes can catalyze lipid peroxidation of the viral lipid envelope to inactivate enveloped viruses and provide protection from viral transmission and infection.
Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)
Authors: P.A. Konstantinopoulos, A.E. Wahner Hendrickson, R.T. Penson, A. Doyle, E.C. Kohn, L.R. Duska, M.A. Crispens, A.B. Olawaiye, I.S. Winer, L.M. Barroilhet, S. Fu, M.T. McHale, R.J. Schilder, A. Farkkila, J. Curtis, R. Quinn, C. Whalen, G.I. Shapiro, U.A. Matulonis
Journal: Annals of Oncology (2019)
High incidence of venous thromboembolic events (VTE) in patients with diffuse large b-cell lymphoma
Authors: A.O. Abufara, M. Ma’koseh, A. Mansour, M. Manasrah, M. Al-Rawashdeh, M. Almomani, M. Zmaily, R. Amarin, H. Abdel-Razeq
Journal: Annals of Oncology (2019)
Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups
Authors: J Martin Broto, A. Italiano, R M Alvarez Alvarez, I. Rincon, J. Peinado, P. Sargos, A. Alvarez, P. Luna, A Lopez Pousa, A. Redondo, I. Alastuey, J. Isern, B. Belinchon, A. Gutierrez, C. Romagosa, K. Marie, C. Morosi, J.-Y. Blay, A. Gronchi, N. Hindi
Journal: Annals of Oncology (2019)